Picture of Corline Biomedical AB logo

CLBIO — Corline Biomedical AB News Story

0.000.00%
se flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapSucker Stock

Brief: Corline Biomedical: Results Of First Study Of Drug Candidate Renaparin

June 10 (Reuters) - Corline Biomedical AB  CLBIO.ST :
    * DRUG CANDIDATE RENAPARIN SHOWS GOOD SAFETY PROFILE IN
FIRST
STUDY ON PATIENTS
    * RENAPARIN HAS GOOD RESULTS FOR BOTH PRIMARY AND SECONDARY
PHASE
1 ENDPOINTS
    * NEXT STEP IN DEVELOPMENT OF RENAPARIN EXPECTED TO BE
COMMUNICATED IN SEPTEMBER 2020

Source text for Eikon:  ID:nGNECKL0G 
Further company coverage:  CLBIO.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))

Recent news on Corline Biomedical AB

See all news